Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00360737 · ClinicalTrials.gov registry record · Phase 1
Safety Study of 7 Botulinum Antitoxin Serotypes Derived From Horses
A Phase 1 study, sponsored by Emergent BioSolutions.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00360737 is a Phase 1 study that has completed, run by Emergent BioSolutions. The registered enrollment target is 40 participants.
The verdict
NCT00360737, a Phase 1 study, has completed, sponsored by Emergent BioSolutions.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The primary purpose of the study is to evaluate the safety of the 7 Botulinum Antitoxin Serotypes derived from horses using various laboratory measurements, clinical examinations and adverse events. In addition, following intravenous (injected into the vein) administration assessing how much 7 Botulinum Antitoxin remains in the body.
Interventions
- BIOLOGICAL Botulinum Antitoxin Heptavalent (A B C D E F G) - (EQUINE)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2006-07 |
| Est. Completion | 2010-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00360737
The ClinicalTrials.gov registry entry for NCT00360737 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emergent BioSolutions, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Botulinum Antitoxin Heptavalent (A B C D E F G) - (EQUINE) is the first listed.
NCT00360737 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00360737 about?
NCT00360737 is a clinical study titled "Safety Study of 7 Botulinum Antitoxin Serotypes Derived From Horses". The primary purpose of the study is to evaluate the safety of the 7 Botulinum Antitoxin Serotypes derived from horses using various laboratory measurements, clinical examinations and adverse events. In addition, following intravenous (injected into the vein) administration assessing how much 7 Botul...
What is the current status of trial NCT00360737?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2006-07. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00360737?
The interventions under investigation include: Botulinum Antitoxin Heptavalent (A B C D E F G) - (EQUINE) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00360737?
This trial is sponsored by Emergent BioSolutions, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.